amgn

When IBM raised its buyback authorization by $10 billion on Oct. 26, it was the 259th company to announce repurchase plans in October alone. Citi Investment Research says a long-term trend of rising buybacks has only just begun.

The pharmaceutical sector was on fire Monday, with successful trials, FDA approvals, and some deal action. So far, Tuesday is shaping up to be similar. Big pharma takes its hits for questionable practices. But on days like these, we remember the enormous value and contributions that drug companies...

Is Facebook actually cash-flow positive? Could this lead to another Internet IPO boom? __________________ Short interest is at its lowest levels since February 2007. What does this mean? __________________ Uber-investor DE Shaw has been loading up on shares of Priceline (PCLN). __________________

No doubt, Amgen (AMGN) and its investors would have liked the U.S. Food and Drug Administration's health panel proceedings to have gone differently. The good news coming out of the panel, held on Thursday, was that Amgen's highly anticipated bone drug, denosumab, benefits patients with...

It's great when a biotech company can deliver on a promising drug. Although Amgen Inc. (AMGN) reported disappointing earnings in the first quarter, many investors put their hopes up on its experimental denosumab bone drug for treating post-menopausal osteoporosis. This drug, which was filed for...

Investors have long heard of the problems plaguing Big Pharma, especially blockbuster drugs coming off patent in the near future, exposing them to competition from cheaper generics. A record number of drug sales will come off patent in the upcoming "patent cliff" arriving in 2010-2012. BusinessWeek...

Amgen Inc. (AMGN) reported first-quarter results after the closing bell yesterday. The world's biggest biotechnology company said its net income, on an adjusted basis, fell 8 percent to $1.12 billion, or $1.08 per share as sales slumped. Revenue decreased 8 percent to $3.3 billion. The results were...